SRR604456
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.441
- INFLAMMATORY_RESPONSE+0.417
- ANGIOGENESIS+0.404
- COMPLEMENT+0.387
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.374
- ALLOGRAFT_REJECTION+0.372
- KRAS_SIGNALING_UP+0.354
- PANCREAS_BETA_CELLS+0.331
- INTERFERON_GAMMA_RESPONSE+0.321
- COAGULATION+0.320
Top 10 suppressed
- MYC_TARGETS_V1-0.515
- MYC_TARGETS_V2-0.481
- E2F_TARGETS-0.474
- DNA_REPAIR-0.443
- PROTEIN_SECRETION-0.416
- G2M_CHECKPOINT-0.355
- UNFOLDED_PROTEIN_RESPONSE-0.324
- CHOLESTEROL_HOMEOSTASIS-0.316
- OXIDATIVE_PHOSPHORYLATION-0.289
- MITOTIC_SPINDLE-0.273
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598337 | fetal | fetal | 0.939 |
| 2 | MDT-AP-0567 | Med | Medulloblastoma | 0.937 |
| 3 | SRR1335707 | GTEX | — | 0.932 |
| 4 | BS_3H71BH6Q | Ganglioglioma | — | 0.925 |
| 5 | SRR1478946 | GTEX | — | 0.922 |
| 6 | ERR2598314 | fetal | fetal | 0.921 |
| 7 | SRR598124 | GTEX | — | 0.920 |
| 8 | GSM5359443 | — | — | 0.919 |
| 9 | BS_3XY76V8T | Ganglioglioma | — | 0.918 |
| 10 | SRR1334033 | GTEX | — | 0.918 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.441 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.417 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.404 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.387 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.374 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.372 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.354 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.331 | Cobimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.321 | Idelalisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| MYOGENESIS | 0.301 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.284 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.279 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.272 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.262 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.252 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.217 | Inavolisib | — uncovered |